Advances in the Management of Severe Asthma: From Phenotyping to Personalized Treatment
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 2478
Special Issue Editors
Interests: sleep apnea; airways disease; severe asthma; COPD; respiratory infections
Special Issues, Collections and Topics in MDPI journals
Interests: sleep disorders; asthma; COPD; smoking cessation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Asthma is a common, chronic airway disease, affecting 1–18% of the population in different countries. It is estimated that in 3–10% of asthmatics, control of the disease cannot be achieved despite adherence to optimized high-dose ICS-LABA therapy and treatment of contributory factors, or the disease worsens when high-dose treatment is decreased.
The management of severe asthma can pose a significant burden on healthcare systems and usually requires referral to specialized centers. From a patient’s perspective, there is a tremendous negative impact on their quality of life by experiencing symptoms refractory to high-dose inhaled treatment, unexpected exacerbations and side effects of medication. Furthermore, severe asthma also interferes with family, social and working life, and affects emotional and mental health.
In recent years, a better understanding of the pathogenic pathways and the rise of biologic therapy in the field of severe asthma have marked significant progress in the management of this condition. Phenotyping of severe asthma patients has become part of routine practice, allowing for the administration of targeted therapies.
Clinical experience with these new therapeutic agents is still limited and there are many unanswered questions regarding long-term safety issues, duration of treatment, optimal frequency of administration, switching between different agents, modulation of inhaled medication, etc. Real-life evidence is still quite scarce.
Given the extremely high interest in this topic of both researchers and medical practitioners, Medicina is launching a Special Issue entitled “Advances in the Management of Severe Asthma: From Phenotyping to Personalized Treatment”. The aim of this Special Issue is to foster both cutting-edge research reports and insights from clinical experience.
We are pleased to invite submissions of original articles reporting on basic and clinical research in severe asthma, as well as interesting case reports, perspectives, reviews, systematic reviews and meta-analyses focusing on topics such as:
- New targets for biologic therapy;
- Optimization of inhaled treatment;
- Real-life effectiveness of biologic agents;
- Long-term safety of biologics in severe asthma;
- Cost/effectiveness ratio of personalized treatment in severe asthma.
Dr. Stefan Frent
Dr. Stefan Mihaicuta
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- severe asthma
- phenotypes
- biologic agents
- long-term safety
- economic burden
- effectiveness
- inhaled treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
